Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
Treatment with the oral antiviral Tamiflu (oseltamivir) and prophylaxis for people exposed to infected patients could be one of the most cost-effective strategies for reducing illness and death during an influenza pandemic.
Adults who have recovered from the potentially deadly H5N1 strain of avian influenza may hold the key to future treatments for the virus, according to an international team of researchers.
LigoCyte Pharmaceuticals has presented preclinical data showing that immunization with their influenza virus-like particles (VLPs) induced heterosubtypic protection in a virus challenge study.
An influenza vaccine produced with the use of insect cells appeared safe and produced an immunogenic response in healthy adults, suggesting promise as an alternative to using embryonated eggs for the development of influenza vaccine, according to a preliminary study in the April 11 issue of JAMA.
Scientists and public health officials, wary that the H5N1 avian influenza virus could trigger an influenza pandemic, have looked to past pandemics, including the 1918 "Spanish Flu," for insight into pandemic planning.
Scientists in Britain believe a 90 year old corpse may hold the answer to the fight against bird flu.
Four million people die every year from respiratory diseases such as viral influenza. For elderly people in particular, an infection can be dangerous. What is more, the flu vaccine is not as effective with this risk group as it is with younger people.
Scientists at the U.S. Centers for Disease Control and Prevention (CDC) have found that just two small changes in the virus that caused the 1918 Spanish flu pandemic stopped it from jumping between mammals in the laboratory.
The first human trial of a DNA vaccine designed to prevent H5N1 avian influenza infection began on December 21, 2006, when the vaccine was administered to the first volunteer at the National Institutes of Health (NIH) Clinical Center in Bethesda, MD.
Federal scientists have developed a vaccine that protects mice against the killer 1918 influenza virus. They also have created a technique for identifying antibodies that neutralize this virus, a tool that could help contain future pandemic flu strains.
Sanofi pasteur, the vaccines business of the sanofi-aventis Group, began shipping influenza vaccine (Fluzone, Influenza Virus Vaccine) to the U.S. market for the 2006-2007 season.
Scientists in the United States have developed a new technology that reduces the time it takes to achieve a detailed diagnosis of avian flu, from one week or more down to less than 12 hours.
Scientists from the University of Colorado at Boulder and the Centers for Disease Control and Prevention (CDC) have developed a microchip-based test that may allow more labs to diagnose influenza infections and learn more about the viruses causing illness.
For the past four days, Indonesian health authorities and WHO have been monitoring cases of influenza-like illness in four nurses who were involved in the care of confirmed H5N1 patients.
The emergence of the avian influenza virus H5N1 that is currently devastating chicken flocks in many countries and threatening to unleash a worldwide epidemic among humans has triggered a renewed interest among scientists in studying influenza A viruses, according to investigators at St. Jude Children's Research Hospital.
Copper could help prevent the spread of flu infections. Recent research at the University of Southampton shows that the Influenza A virus is virtually eradicated within six hours on copper surfaces.
A study published today in the open access journal Respiratory Research reveals that, in human cells, the virus can trigger levels of inflammatory proteins more than 10 times higher than the common human flu virus H1N1.
A novel "Flu Chip" developed at the University of Colorado at Boulder that can determine the genetic signatures of specific influenza strains from patient samples within hours may help world health officials combat coming epidemics and pandemics.
New Zealanders who were immunised against influenza last year are likely to have some protection against the current influenza viruses hitting schools around the country.
The HPA Influenza Pandemic Contingency Plan outlines the Health Protection Agency’s plan for responding to an influenza pandemic. It replaces the Public Health Laboratory Service Pandemic Influenza Plan of July 2001.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.